Alleyba says............................
................that over the past 8-10 months Alleyba has found the CEO to be very credible in what he has been saying. Most of the people Alleyba suggested to buy this stock was done under hype of the Rapimeds and yes Alleyba was disappointed when that seemed to be going nowhere. Then Bob decided to shift gears and enter the compounding aspect of the business and revenues started to explode. Yes, pror to the compounding we were also mired in toxic paper. Alleyba's opinion was that it took alot of guts to shift gears in the midst of the Rapimeds hype and move to compounding.
Then the announcements started to come as follows (1) SCRC was paying off the toxic notes (2) expansion into other states and (3) announcement of the Rapimeds order. The compunding has been explosive, the reduction of toxic notes has all but been eliminated and imo the delay with Rapimeds has been due to SCRC never have done business before in Asia and did not anticipate all the red tape and legaliities involved in doing business there but contrary to some other posters imo the $200,000 will ultimately be delivered and the question then becomes can they then handle all the new orders that will subsequently follow? The Asians love American pharmacy products. But will it stop in Asia? Alleyba believes now that SCRC knows "the ropes" in dealing overseas they will hopefully move to other countries.
Now Alleyba admits he is no genius, but the compounding, even if they do the same numbers each month going forward should give company a minimum $12 milion dollar run rate for the 3rd quarter. Now throw in the expansion into other states, throw in the RX which Alleyba believes is about to explode and factor in PIMD. To Alleyba that appeas to make this a cash flow positive company..........then lo and behold Wall Street takes notice and then Alleyba beleives we are off to the races. Once Wall Street sees the Rapidmeds delivery and the news that SCRC is cash flow positive would anyone disagree that right now this stock is grossly UNDERVALUED. The profitability on the compounding, RX and Rapimeds is mind blowing.
In conclusion Alleyba believes this stock is a strong buy based on the above.
................that over the past 8-10 months Alleyba has found the CEO to be very credible in what he has been saying. Most of the people Alleyba suggested to buy this stock was done under hype of the Rapimeds and yes Alleyba was disappointed when that seemed to be going nowhere. Then Bob decided to shift gears and enter the compounding aspect of the business and revenues started to explode. Yes, pror to the compounding we were also mired in toxic paper. Alleyba's opinion was that it took alot of guts to shift gears in the midst of the Rapimeds hype and move to compounding.
Then the announcements started to come as follows (1) SCRC was paying off the toxic notes (2) expansion into other states and (3) announcement of the Rapimeds order. The compunding has been explosive, the reduction of toxic notes has all but been eliminated and imo the delay with Rapimeds has been due to SCRC never have done business before in Asia and did not anticipate all the red tape and legaliities involved in doing business there but contrary to some other posters imo the $200,000 will ultimately be delivered and the question then becomes can they then handle all the new orders that will subsequently follow? The Asians love American pharmacy products. But will it stop in Asia? Alleyba believes now that SCRC knows "the ropes" in dealing overseas they will hopefully move to other countries.
Now Alleyba admits he is no genius, but the compounding, even if they do the same numbers each month going forward should give company a minimum $12 milion dollar run rate for the 3rd quarter. Now throw in the expansion into other states, throw in the RX which Alleyba believes is about to explode and factor in PIMD. To Alleyba that appeas to make this a cash flow positive company..........then lo and behold Wall Street takes notice and then Alleyba beleives we are off to the races. Once Wall Street sees the Rapidmeds delivery and the news that SCRC is cash flow positive would anyone disagree that right now this stock is grossly UNDERVALUED. The profitability on the compounding, RX and Rapimeds is mind blowing.
In conclusion Alleyba believes this stock is a strong buy based on the above.
